• Earlier this month, Chemours launched Opteon ZE (R-1234ze(E)) and Opteon 515B (R-515B), ultra-low and low-GWP refrigerants for stationary chillers and data center cooling, expanding its Opteon portfolio for large-scale applications.
• The move underlines Chemours’ push into higher-value, climate-focused refrigerants for AI and data center infrastructure, while broader Opteon aftermarket demand headwinds and ongoing losses frame a complex backdrop.
• We’ll now examine how Chemours’ new low-GWP Opteon refrigerants for data centers influence its investment narrative built around regulatory-driven growth.

The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Chemours Investment Narrative Recap

To own Chemours, you need to believe that regulatory-driven demand for low GWP refrigerants and higher value specialty applications can ultimately outweigh ongoing losses, PFAS overhang, and volatile TiO2 cycles. The new Opteon ZE and 515B launches broaden Chemours’ reach into AI and data center cooling but do not immediately change the key near term swing factor, which is weaker Opteon aftermarket demand and its impact on near term earnings.

The most relevant recent announcement is Chemours’ updated 2026 outlook, which now calls for a full year net loss of US$255 million to US$230 million, despite targeting 1% to 5% net sales growth. This frames the Opteon data center products as a longer term opportunity arriving while the company is still contending with weak aftermarket refrigerant demand, elevated interest costs, and unresolved PFAS liabilities.

Yet behind the appeal of climate friendly Opteon growth, investors should also be aware of the unresolved PFAS litigation exposure and the potential for...

Chemours' narrative projects $6.8 billion revenue and $1.3 billion earnings by 2029. This requires 5.1% yearly revenue growth and a roughly $1.7 billion earnings increase from -$410.0 million today.

Uncover how Chemours' forecasts yield a $24.67 fair value, a 56% upside to its current price.

Exploring Other Perspectives

While consensus ties Chemours’ story to gradual Opteon growth and ongoing losses, the most optimistic analysts were assuming revenue could reach about US$7.2 billion and earnings US$1.4 billion by 2029, so this new data center push may either reinforce that upbeat view or force everyone to rethink how much risk still sits in Opteon and PFAS.

Explore 4 other fair value estimates on Chemours - why the stock might be worth over 2x more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Chemours research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Chemours research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Chemours' overall financial health at a glance.

Want Some Alternatives?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.
• Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Find 50 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.